Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,626.00
Bid: 13,344.00
Ask: 11,836.00
Change: 36.00 (0.29%)
Spread: -1,508.00 (-11.301%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK public sector borrowing shoots up in November

Wed, 21st Dec 2022 07:55

(Alliance News) - Stock prices in London were called to open higher on Wednesday, after a positive finish on Wall Street.

In early economic news, public sector net borrowing in the UK jumped in November due to the energy support scheme, according to the Office of National Statistics.

It reached a total of GBP21.20 billion, surpassing the GBP13.37 billion in October, which was revised upwards from GBP12.73 billion.

"Public borrowing was boosted in November by the government's energy and cost of living interventions, the decision to reverse April's National Insurance hike, and high inflation," said Pantheon Macroeconomics' Samuel Tombs.

"The Energy Bills Support Scheme cost the government GBP1.9 billion in November, while the Energy Price Guarantee was the main driver of a GBP4.7 billion year-over-year rise in subsidies. In addition, social assistance payments were GBP3.3 billion higher than a year ago, reflecting the payment of the second Cost of Living grants to working-age benefit recipients," Tombs continued.

Meanwhile, consumer confidence in Germany is expected to improve for the third month in a row in January.

The latest GfK forecast is minus 37.8 points for its consumer sentiment index, which is up 2.3 points from the revised figure of minus 40.1 points in December.

Economic and income expectations have improved, as has the propensity to buy.

"The consumer sentiment is thus continuing its cautious recovery. More moderate energy prices than originally expected and the German government's relief packages to curb energy costs are responsible for the decreased pessimism," GfK explained.

In early corporate news, Bunzl said it expects double-digit revenue growth in 2022, while AstraZeneca won two new drug approvals in the EU.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called up 25.5 points, 0.4%, at 7,396.12

----------

Hang Seng: down 0.1% at 19,079.08

Nikkei 225: closed down 0.7% at 26,387.72

S&P/ASX 200: closed up 1.3% at 7,115.10

----------

DJIA: closed up 92.20 points, or 0.3%, at 32,849.74

S&P 500: closed up 3.96 points, or 0.1%, at 3,821.62

Nasdaq Composite: closed up just 1.08 points at 10,547.11

----------

EUR: lower at USD1.0613 (USD1.0627)

GBP: higher at USD1.2156 (USD1.2139)

USD: lower at JPY132.24 (JPY131.27)

GOLD: lower at USD1,814.06 per ounce (USD1,814.62)

OIL (Brent): flat at USD80.31 a barrel (USD79.88)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

11:00 GMT UK CBI distributive trades survey

07:00 EST US MBA weekly mortgage applications survey

10:00 EST US consumer confidence index

----------

An estimated 1.9 million UK households have missed payments in the run-up to Christmas, according to Which? The consumer group combined the findings from a survey of 2,000 people with population figures to make the calculations. The survey found that around 6.7% of households had missed or defaulted on at least one mortgage, rent, bill or credit payment in the past month in December – which could equate to 1.9 million households if the findings were projected across the UK.

----------

Ukraine's President Volodymyr Zelensky will meet US leader Joe Biden and address Congress in Washington on Wednesday, a visit the White House said will send Russia a strong message of Western unity. The secretly arranged trip comes on the same day Russian President Vladimir Putin plans to meet his top military officials to assess the dire results so far of the war on Ukraine and set goals for next year. The visit will "underscore the US' steadfast commitment to supporting Ukraine for as long as it takes," White House spokeswoman Karine Jean-Pierre said in a statement. It will be Zelensky's first trip outside Ukraine since Russian forces invaded in February.

----------

BROKER RATING CHANGES

----------

Citigroup cuts British Land price target to 388 (526) pence - 'neutral'

----------

RBC raises Close Brothers price target to 1,350 (1,100) pence - 'outperform'

----------

COMPANIES - FTSE 100

----------

Bunzl said it expects to deliver strong growth in 2022, with revenue set to grow 17% year-on-year. This is due to "inflation driving underlying revenue growth and the impact of acquisitions further supplementing growth", the distribution services firm said. Bunzl said its operating margin is expected to be slightly ahead of prior guidance, and will be in line with 2021. Looking ahead to 2023, Bunzl expects revenue to grow slightly, with adjusted operating profit to be "resilient". Adjusted earnings per share are expected to be "moderately" lower from 2022, however. "Negotiations with our largest customer by revenue are ongoing," Bunzl noted.

----------

AstraZeneca received approvals for Lynparza and Imfinzi in the EU. Lynparza, or olaparib, has been approved as a combination treatment for the treatment of metastatic castration-resistant prostate cancer. The approval was based on the results from its Propel phase III trial. Imfinzi, or durvalumab, has been approved as a first-line treatment in combination with chemotherapy for unresectable or metastatic biliary tract cancer. The approval is based on primary results from the Topaz-1 phase III trial.

----------

Anglo American said De Beers rough diamond sales amounted to USD410 million in its tenth sales cycle of 2022, which was down from USD454 million in cycle nine. It was up from USD336 million in the tenth cycle of 2021, however. "Demand for our rough diamonds over the final sales cycle of 2022 was in line with expectations, ahead of the normal seasonal closure of polishing factories in southern Africa over the Christmas period and with Sightholders taking a prudent approach ahead of restocking after Christmas and the expected re-opening of the China market," said CEO Bruce Cleaver. The figures for cycle 10 remain subject to adjustment.

----------

COMPANIES - FTSE 250

----------

Ferrexpo said it is now receiving sufficient power levels to bring one pelletiser line back into operation in Ukraine. "This will allow the group, together with its stockpiled material, to meet the requirements of existing customer contracts," it explained. The iron pellet producer had suspended its operations in central Ukraine back in October. Ferrexpo said it has produced around 300,000 tonnes of pellets in the fourth quarter so far, and expected total pellet production for 2022 to be around 5.9 to 6.0 million tonnes. "Despite interruptions to the group's production, shipments to customers during 4Q 2022 have continued at a run rate of approximately 250 kilotonnes per month," it noted.

----------

Security contractor Serco will be sentenced later for health and safety failings that led to a mentally-ill prisoner kicking a custody officer to death. Humphrey Burke, now 29, attacked 54-year-old Lorraine Barwell as she tried to escort him from his cell in Blackfriars Crown Court in central London in June 2015. Burke admitted manslaughter by diminished responsibility and was handed an indefinite hospital order at the Old Bailey in January. Barwell's employer, Serco, which is contracted by the Ministry of Justice to provide security services in courts, pleaded guilty in April to one count of failure to discharge general health, safety and welfare duty from January 2014 to March 2017.

----------

OTHER COMPANIES

----------

Directa Plus announced a "new significant" contract with European speciality chemical and ingredient distributor Pigmentsolution. The producer and supplier of graphene nanoplatelets based products said it will support the development of its new Grafyshield G+ product in Europe. The contract will initially run for 12 months from January, in Germany, Austria, Switzerland and Poland. The contract will enable "Directa Plus to assess these important markets to build a solid basis for 2024", and assess potential expansion across Europe in the longer-term.

----------

Mitsui & Co subsidiary Mitsui USA enters into agreements with Florence Copper for copper cathode offtake and an equity conversion right. Florence plans to produce low-carbon copper cathode in Arizona, and Mitsui will pay USD50 million to cover part of the development costs. Says Florence plans to produce copper using the in-situ recovery for extracting the metal from underground deposits. Expects construction to take 18 months, and then production will start. Florence is a subsidiary of Taseko Mines, which is listed in Toronto, New York and London.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.